Upcoming Issue Highlights

Daiwa Health Development, Inc.

1411 W. 190th St., Ste. 375
Gardena, CA 90248
Phone: (877) 434-3633 • Fax: (877) 434-3644
Email: info@dhdmed.com
Website: www.dhdmed.com

Slowing the Progress of Immuno-senescence

The term immune-senescence was coined by the late researcher of gerontology Dr. Roy Walford in the late 1960s. The expression succinctly defines the progression of a declining immune system over time, which leads to the aging process and anticipated decline in health that is accepted as “normal” in both humans and animals.1 Because of immune-senescence, the elderly are vulnerable to serious infectious diseases and a poor response to vaccinations. For example, the 2012-2013 flu vaccination was reported to have only 9 percent effectiveness against influenza A in seniors over 65 years of age, versus 52 percent in adults under 65.2 Numerous reasons account for this weakened immune response, including a decline in hematopoietic stem cell activity and ability to produce B cells; a shrinking thymus which results in lower T cell production; and telomere shortening.3

If the deterioration of the immune system is largely responsible for the aging process, then investing in immune supportive therapies could be fundamental to enhance longevity and health.

Augmenting the immune system should start with improving one’s lifestyle; smoking, drinking alcohol, poor sleep habits and an unhealthy diet can all suppress immune cell function and must be minimized. But is there more that can be done to supercharge the immune system and delay the degeneration process?

One exceptionally effective immune enhancing nutrient is called BRM4. The active ingredient in BRM4 is rice bran Arabinoxylan compound (RBAC), which is a natural polysaccharide composed of hemi-cellulose extract from rice bran modified by an enzyme derived from shiitake mushroom. The resulting Arabinoxylan compound is a smaller molecule than the rice bran extract, which it was derived from, making it more bio-available and better absorbed. Extensive scientific research has been conducted on RBAC, which confirm its impact on the immune system; it consistently increases natural killer (NK) cell activity, and significantly enhances B and T cell count in individuals with compromised immune systems.4 RBAC is particularly unique because it is a proven immune-modulator, a term defined by one researcher as “an agent possessing a broad range of activity dependent upon the existing state of health and immunity in the individual host.”5

In one published clinical trial, the enzymatically-treated rice bran was shown to increase NK cell activity in a dose dependent manner. Twenty-four individuals took the compound at three different concentrations: 15, 30, 45 mg/kg/day. The activity of NK cells was measured after taking the extract for one week, one month and two months. The results of the study showed that all doses increased the activity of NK cells, but the larger the dose, the quicker the NK activity increased. After two months of treatment, NK activity peaked to the same level regardless of the dosage. One month after discontinuing treatment, NK activity levels declined to baseline levels. This study proved valuable in making dosage recommendations; immune compromised persons should take a high initial dose of the supplement to boost NK activity quickly. After a few weeks, a high level of NK activity could be maintained long term on a lower maintenance dose level.6

A more recent study at the University of Miami included 20 healthy individuals and determined that immune activity starts to increase within as little as two days, and becomes significant after one week of taking RBAC. This study also demonstrated the bi-directional immune marker effects that are expected with a proper immune-modulator.7

Several clinical and reported case studies have demonstrated a significant positive clinical effect from RBAC. One specific clinical trial showed that RBAC helped improve the quality of life for people with stage III-IV cancer when taken in conjunction with standard cancer therapies. In this study, the people in the control group used only standard cancer therapies and were found to have poor appetites with subsequent weight loss, extreme fatigue and high mortality rates. The group taking RBAC in conjunction with standard treatment experienced improved appetites, and significantly higher survival rates.8

RBAC has been the subject of 40 published studies to date, and a multitude of case studies have been collected from physicians around the world. RBAC is found exclusively in a product called BRM4, manufactured by Daiwa Health Development, and is available at top physician-grade distributors.

References:

1 Immunity & Ageing 2005, 2:7.

2 www.cdc.gov/flu/about/season/flu-season-2012-2013.htm.

3 EMBO Reports (2007) 8, 220–223.

4 Townsend Letter for Doctors and Patients January 2000:58-62.

5 Functional Foods in Health and Disease 2012, 2(7):265-279

6 Int J Immunotherapy 14(2) 89-99, 1998.

7 Functional Foods in Health and Disease 2012, 2(7):265-279.

8 Clinical Pharmacology and Therapy 2004; 14(3).